More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea
Author: Joan McKenna
The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. The Justice Department, in a complaint filed March 28 under the False Claims Act and announced April 10, alleges that Regeneron inflated Eylea’s average sales price (ASP) by paying credit card processing fees for the benefit of physicians purchasing Eylea, without properly reporting these payments as...
